In vitro studies on the action of CS-045, a new antidiabetic agent

Metabolism: Clinical and Experimental
T P CiaraldiK A Heidenreich

Abstract

The mechanism of action of CS-045, a new orally active antidiabetic agent, was studied in vitro using cultured hepatoma cells (Hep G2) and muscle cells (BC3H-1). Treatment of both types of cultured cells with varying doses of CS-045 did not significantly alter insulin receptor binding. Basal and insulin-stimulated glucose transport in BC3H-1 cells was also unaltered by the drug. In contrast, CS-045 increased glycogen synthase I activity in both cell types. This effect was maximal after 24 hours and in Hep G2 cells was associated with a threefold increase in the apparent affinity of the enzyme for glucose-6-phosphate. Gluconeogenesis from lactate in Hep G2 cells was greatly reduced by CS-045 treatment. We conclude that CS-045 may act directly on muscle and liver cells to increase glucose utilization. It is also effective in reducing glucose production. These multiple effects may account in part for the ability of CS-045 to reduce blood sugar levels in vivo.

Associated Clinical Trials

References

Jan 1, 1979·Annual Review of Biochemistry·E G Krebs, J A Beavo
Jul 1, 1978·The Journal of Clinical Investigation·M Kobayashi, J M Olefsky
Nov 9, 1978·Nature·M N Feinglos, H E Lebovitz
Jul 15, 1985·European Journal of Biochemistry·J M PodskalnyP Gorden
Jul 1, 1988·The Journal of Clinical Endocrinology and Metabolism·E J VerspohlI D Goldfine
Jan 1, 1989·The Journal of Clinical Investigation·A BrunettiI D Goldfine
Nov 1, 1986·Diabetes·S S SolomonM Palazzolo
Nov 15, 1988·Biochemical Pharmacology·N Wollen, C J Bailey
Oct 1, 1987·Metabolism: Clinical and Experimental·M B Davidson, G Sladen
Nov 28, 1988·The American Journal of Medicine·F Q NuttallA W Tan
Jul 1, 1986·Diabetes·J ForsayethI D Goldfine
Sep 20, 1985·The American Journal of Medicine·J R Gavin
May 1, 1974·The Journal of Cell Biology·D SchubertS Heinemann
Oct 1, 1967·Proceedings of the National Academy of Sciences of the United States of America·H J Mersmann, H L Segal
Sep 1, 1980·The Journal of Clinical Investigation·M J Prince, J M Olefsky
Apr 1, 1981·The Journal of Clinical Investigation·W S PutnamH E Lebovitz
Feb 1, 1982·The Journal of Cell Biology·R MunsonL Glaser

❮ Previous
Next ❯

Citations

Mar 29, 2002·Diabetes/metabolism Research and Reviews·Hans Hauner
Mar 20, 1998·Journal of Clinical Pharmacology·C M LoiJ R Koup
Apr 29, 1998·Journal of Clinical Pharmacology·C M LoiA J Sedman
Oct 16, 2002·Current Cardiology Reports·Annaswamy Raji, Jorge Plutzky
Sep 1, 1995·Metabolism: Clinical and Experimental·M K Lee, J M Olefsky
Mar 28, 2003·Biochemical and Biophysical Research Communications·Agneta HildingMoira S Lewitt
Jul 29, 2000·European Journal of Pharmacology·K UchidaC Shigemasa
Dec 2, 2000·European Journal of Pharmacology·P Raman, R L Judd
Jul 5, 2001·European Journal of Pharmacology·K EtoM Fujishima
Mar 17, 1999·European Journal of Pharmacology·T Kobayashi, K Kamata
Oct 21, 1999·European Journal of Pharmacology·Y SunagaS Seino
Aug 5, 2003·Metabolism: Clinical and Experimental·Marta SanturéHélène Bachelard
Dec 2, 1999·Diabetes Research and Clinical Practice·K ShiraiY Miyashita
Oct 6, 1997·Endocrinology and Metabolism Clinics of North America·R R Henry
Oct 24, 2000·Trends in Endocrinology and Metabolism : TEM·J M Olefsky, A R Saltiel
Feb 2, 2011·Nature Reviews. Drug Discovery·Masanobu KawaiClifford J Rosen
Sep 8, 2010·Nature Reviews. Endocrinology·Masanobu Kawai, Clifford J Rosen
Jan 8, 1998·British Journal of Pharmacology·C FürnsinnW Waldhäusl
Sep 13, 2001·Clinical and Experimental Pharmacology & Physiology·J YoshiokaT Nishimura
Jun 20, 2001·Diabetes, Obesity & Metabolism·A J Stears, C D Byrne
Mar 5, 2002·Diabetes, Obesity & Metabolism·D E Kelley
May 5, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·C Day
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Nov 3, 1994·The New England Journal of Medicine·H Keen
Mar 27, 1998·The New England Journal of Medicine·S E InzucchiG I Shulman
Mar 11, 1998·Clinical and Experimental Pharmacology & Physiology·R Donnelly, X Qu
Aug 1, 1994·Diabetic Medicine : a Journal of the British Diabetic Association·K MimuraH Nawata
Jun 1, 1995·Diabetic Medicine : a Journal of the British Diabetic Association·J Rachman, R C Turner
May 1, 1996·Photochemistry and Photobiology·Y FuC S Foote
Jun 11, 2002·Annual Review of Nutrition·Frédéric Picard, Johan Auwerx

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.